Key Takeaways
- Revenue flat, margin squeezed: Q4 revenue was nearly flat YoY, but EBITDA margin fell as operating costs, acquisition integration, and raw material inflation hit simultaneously.
- Full-year tells the real story: Management argues FY26's full-year trajectory, not the noisy Q4, represents underlying momentum, with a ~30% revenue CAGR targeted over the next three years.
- Balance sheet stretched, but levers exist: Inventories and receivables ballooned, pushing cash flow negative, yet management is enforcing stricter payment terms and expects positive cash flow by FY27-end.
- Capacity build-out underway: Combined installed capacity reached 1,400–1,600 MT post-acquisitions, with a new facility commissioning by Q1 FY28 and FY28 revenue targeted at ₹700–800 crore.
- What to watch next quarter: Whether the promised 20–25% inventory reduction materializes by Q2, the pace of receivable days improvement, and any update on the unanswered Remember Pharma acquisition question.
Margin Dynamics
- Q4 margin compression: EBITDA margin declined despite flat revenue, driven by costs of becoming a more professional and system-driven company, expenses from two newly acquired facilities, and raw material price increases from the war situation where the company held purchase orders at previous prices without passing increases to customers.
- Raw material volatility is structural now: Prices of most common solvents and raw materials now carry validity of only one day, forcing rapid confirmation decisions and squeezing supplier credit terms from 90 days to 45–60 days.
- Consolidated margin target: Management expects 30–35% EBITDA margin for FY27 on ₹380–400 crore topline, but the conservative consolidated figure is 25%, with specialty chemicals pulling slightly lower than pharma margins.
- War-linked uncertainty: Margin maintenance depends on a return to pre-war normalcy in raw material pricing, though management insists it will not sell below a level that damages EBITDA margin.
Punit Rasadia: "If things will be normal as per the pre-war situation, then we'll able to maintain the same EBITDA margin, otherwise it may impact on the EBITDA margin, but definitely we'll have the better pricing also in terms of the selling price."
Working Capital & Cash Flow
- Receivable days elevated: Currently ~130–140 days, with 50% of sales sitting in receivables because last-quarter sales plus 90-day payment terms stretch recovery to 120–130 days; management says below 180 days is impossible for an API manufacturer.
- Cash flow turned negative: Delayed payments from a distributor/customer drove the shortfall, but a new policy of stopping supply if payment is not made within 120 days is already improving recovery.
- Customer leverage demonstrated: One listed pharma company was paying beyond 120 days despite a 45-day requirement; Anlon stopped supply, and because Anlon is part of their DMF, the customer could not switch suppliers immediately and is now paying at ~60–65 days.
- Inventory build-up explained: Inventories rose due to the Apiqo and Bizotic acquisitions plus raw material prices more than doubling in most categories; three months of inventory is considered normal, and a 20–25% reduction is expected by Q2 FY27.
- Positive cash flow commitment: Management is "100% sure" of positive cash flow from operations on an annual basis by end of FY27.
Punit Rasadia: "We have stopped the supply to them because we are the part of their drug master file for one of our KSM. So they cannot change the supplier immediately if I'll not supply to them, just on the basis of the payment terms and prices."
Capacity Expansion & Capex
- Acquisitions adding scale: Apiqo Organics (acquired first week of January) strengthened backward integration and added substantial capacity; Bizotic Life Science (acquired mid-quarter) accelerated capacity expansion and regulatory readiness; combined installed capacity now approximately 1,400–1,600 MT per annum.
- New facility timeline: Construction starts by end of this month or early next month, with commissioning expected by Q1 FY28 and commercial production in the same quarter.
- FY28 utilization assumption: Management expects 50–60% utilization in the new facility, with six months of working in the expanded setup, supporting FY28 revenue of ₹700–800 crore.
- Peak revenue potential caveated: Current consolidated capacity could theoretically deliver ₹450–500 crore assuming 80% utilization, but management notes practically it is not possible to use more than 85%.
- Funding mix: A term loan of ₹65–70 crore from a bank will cover 50–60% of capex, with the balance from internal funds; no equity dilution is planned currently, though a rights issue or cash credit may be considered for working capital once the new facility commences.
CDMO & Product Pipeline
- Three molecules for two global innovators: These reinforce the long-term strategy for a scalable custom manufacturing platform; one CDMO product has already been supplied at validation stage (multiple of 100 KGs in March).
- Commercialization roadmap: First CDMO product commercial supply expected by Q3 FY27; the other two molecules should reach validation by Q2 FY27, with commercialization by last quarter FY27 or Q1 FY28.
- DMF portfolio activation: Out of 21 DMFs, 5–7 products are expected to be regularly commercialized within FY27 for export, supporting a target of at least 60% of revenue from exports.
- Regulatory milestones: Dexketoprofen DMF has been processed in Europe, with a query from EDQM expected within the next two or three months; Ketoprofen DMF filing in the US is expected by Q2 FY27 but may slip to Q3 or Q4.
- Backward integration benefit: Apiqo will enable in-house production of a backward-integrated intermediate, with benefit expected from Q2 in both profitability and supply chain stability.
Competitive Position & Pricing Power
- Chemistry moat: Anlon holds a process advantage in specific chemistries like methylation and Friedel-Crafts, where it has already cracked the chemistry and driven manufacturing costs to a level where it faces no competition.
- DMF lock-in with customers: Being part of a customer's Drug Master File creates switching costs that give Anlon leverage on payment terms and pricing, as demonstrated when stopping supply forced a delinquent customer back to ~60–65 day payments.
- Raw material pass-through: The company initially held purchase orders at previous prices during the war-driven spike, but has now accepted force majeure and convinced customers to accept price increases.
- Specialty chemicals diversification: Early traction in industrial and fine chemicals is encouraging, though EBITDA margins are slightly lower than pharma, and a higher contribution will take three to six months to show.
Punit Rasadia: "We have the always process upper hand in terms of specific chemistry like methylation and Friedel-Crafts where we have already cracked the chemistry and we have take out the cost of the manufacturing at certain level where we don't have means any competition."
Capital Allocation & Governance
- Acquisition pipeline active: Discussions are underway with entities having marketing and distribution advantages in finished dosage and peptide manufacturing, though no immediate timeline exists and no acquisition is expected in the next 3–6 months.
- Minority stake conversion: Discussions ongoing to convert minority stakes in Bizotic and Apiqo to 100% subsidiaries via a share swap, likely to be taken up at the next AGM.
- Credit rating cleanup: The CARE rating with an "issuer not cooperating" remark is historical (since 2018/19) and stems from Anlon refusing to pay CARE for withdrawal; a fresh rating from Brickwork is expected within 45 days, assured at least triple B minus.
- Shareholder base expansion: A stock split and bonus issue were executed to increase liquidity; the shareholder count rose from a saturated ~11,000 to approximately 25,000.
- Tax rate unresolved: When asked what tax rate to assume for FY27 and FY28, management said "I also need to check" and directed the analyst to get details privately, leaving the question unanswered on the call.
Punit Rasadia: "CARE was doing the literally blackmailing to get the money and doing all that activity and finally we have not given them a single penny for withdrawing that rating, that's why they have published."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue | ₹380–400 crore | FY27 |
| Revenue | ₹700–800 crore | FY28 |
| Revenue CAGR | ~30% over three years | FY26–FY28 |
| EBITDA margin | 30–35% (standalone expectation on ₹380–400 Cr topline) | FY27 |
| EBITDA margin | ~25% consolidated (conservative, sustainable) | FY27 and ongoing |
| PAT | ₹45 crore conservative, realistically ₹50–55 crore | FY27 |
| Cash flow from operations | Positive on annual basis | FY27 |
| Inventory reduction | 20–25% reduction | By Q2 FY27 |
| Receivable days | At least 180 days (below that impossible for API) | FY27-end |
| New facility commissioning | Construction starts month-end; commercial production | Q1 FY28 |
| New facility utilization | 50–60% | FY28 |
| CDMO first product commercial supply | Commercial supply begins | Q3 FY27 |
| CDMO other two molecules | Validation complete | Q2 FY27 |
| CDMO other two molecules | Commercialization | Last quarter FY27 or Q1 FY28 |
| DMF commercialization | 5–7 products regularly commercialized for export | Within FY27 |
| Export contribution | At least 60% of revenue | FY27 |
| Capex funding | ₹65–70 Cr term loan (50–60% of capex), balance internal; no equity dilution | During capex period |
| Credit rating | Fresh Brickwork rating, at least triple B minus | Within 45 days |
| Minority stake conversion | Share swap to make Bizotic and Apiqo 100% subsidiaries | Next AGM |
| Payment terms policy | Not more than 120 days, targeting 90 days | Ongoing |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Total income (consolidated) | ₹50.90 cr, vs ₹48.97 cr in Q4 FY25 |
| Total income FY26 | ₹172.22 cr, +42.98% YoY from ₹120.46 cr in FY25 |
| EBITDA FY26 | ₹47.77 cr, +47.55% YoY |
| PAT FY26 | ₹29.09 cr, +41.77% YoY |
| Q4 PBT | ₹14.44 cr, vs ₹15.49 cr in Q4 FY25 |
| Q4 PAT | ₹11.07 cr, vs ₹16.65 cr in Q4 FY25 |
| FY27 revenue guidance | ₹380–400 cr |
| FY28 revenue expectation | ₹700–800 cr |
| Consolidated EBITDA margin guidance | 24–25% |
| FY27 EBITDA margin expectation | 30–35% (with ₹380–400 cr topline) |
| FY27 PAT expectation | ₹45 cr conservative, realistically ₹50–55 cr |
| Consolidated capacity utilization | 62–65% |
| Combined installed capacity | ~1,400–1,600 metric ton per annum |
| Peak revenue potential (current consolidated capacity) | ₹450–500 cr |
| Order book visibility (FY27, consolidated) | ₹280–300 cr |
| DMF filings | 21 filings; 5–6 products in commercial supply to regulated market |
| Export contribution target (FY27) | ~60% |
| Receivable days | 130–140 days currently; targeting below 180 days by end of FY27 |
| Trade receivables (FY26) | ~₹100 cr, ~60% of FY26 revenue of ₹170 cr |
| Outstanding from distributor | ₹17 cr still outstanding; ₹11 cr recovered |
| New standalone capex | ~₹130 cr; funded ₹65–70 cr via term loan, balance from internal accruals |
| Inventory reduction expected | 20–25% liquidation by Q2 FY27 |
| Shareholder count | ~25,000 after split and bonus, up from ~11,000; target 100,000–150,000 |
| Credit rating | Brickwork withdrew at double B minus; fresh rating expected within 45 days, assured at least triple B minus |